{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T06:38:39Z","timestamp":1759991919208},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"published-print":{"date-parts":[[2005,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Antimicrobial therapy is considered an important component in the medical management of most patients with acute exacerbation of chronic bronchitis (AECB). The three predominant bacterial species isolated are nontypeable<jats:italic>Haemophilus influenzae<\/jats:italic>,<jats:italic>Moraxella catarrhalis<\/jats:italic>, and<jats:italic>Streptococcus pneumoniae<\/jats:italic>.<jats:italic>Staphylococcus aureus<\/jats:italic>is also frequently isolated while atypical bacteria are thought to cause up to 10% of exacerbations. Antibacterial resistance is increasing worldwide and little surveillance data exist concerning pathogens isolated from patients with AECB.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study examines the prevalence of antibacterial resistance in isolates obtained from patients with clinically diagnosed AECB. A total of 3043 isolates were obtained from 85 centres in 29 countries, between 1999\u20132003, and were tested against the new ketolide telithromycin and a panel of commonly used antibiotics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results and Discussion<\/jats:title><jats:p>Of the<jats:italic>S. pneumoniae<\/jats:italic>isolates, 99.9% were susceptible to telithromycin, but only 71% were susceptible to erythromycin and 75.3% to penicillin. Of the<jats:italic>H. influenzae<\/jats:italic>isolates, 99.6% were susceptible to telithromycin. 11.7% of these isolates produced \u03b2-lactamase. Almost 10% of<jats:italic>S. pneumoniae<\/jats:italic>were multidrug-resistant; 99.0% of these isolates were susceptible to telithromycin. Telithromycin also demonstrated good<jats:italic>in vitro<\/jats:italic>activity against<jats:italic>M. catarrhalis<\/jats:italic>(MIC<jats:sub>90<\/jats:sub>= 0.12 mg\/L) and was the most active compound against methicillin-susceptible<jats:italic>S. aureus<\/jats:italic>(98.9% susceptible).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Telithromycin demonstrated similar or better activity against the bacterial species investigated than the other agents, with the most complete coverage overall. These species are the predominant causative bacterial pathogens in AECB and thus the spectrum of activity of telithromycin makes it a potential alternative for the empirical treatment of AECB.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1476-0711-4-5","type":"journal-article","created":{"date-parts":[[2005,3,9]],"date-time":"2005-03-09T07:25:58Z","timestamp":1110353158000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Antibiotic activity of telithromycin and comparators against bacterial pathogens isolated from 3,043 patients with acute exacerbation of chronic bronchitis"],"prefix":"10.1186","volume":"4","author":[{"given":"Sanjay","family":"Sethi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Anzueto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,3,8]]},"reference":[{"key":"50_CR1","volume-title":"The World Health Report 2002. Reducing risks, promoting healthy life","author":"WHO","year":"2002","unstructured":"WHO: The World Health Report 2002. Reducing risks, promoting healthy life. 2002, MDI.WHR.202.A: Geneva , The World Health Organization,"},{"issue":"5","key":"50_CR2","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1164\/ajrccm.163.5.ed1101e","volume":"163","author":"NJ Gross","year":"2001","unstructured":"Gross NJ: The GOLD standard for chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001, 163 (5): 1047-1048.","journal-title":"Am J Respir Crit Care Med"},{"key":"50_CR3","volume-title":"Global Initiative for Chronic Obstructive Lung Disease","author":"GOLD","year":"2003","unstructured":"GOLD: Global Initiative for Chronic Obstructive Lung Disease. http:\/\/wwwgoldcopdcom\/ .2003,"},{"issue":"5 Pt 2","key":"50_CR4","first-page":"S77","volume":"152","author":"ATS","year":"1995","unstructured":"ATS: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med. 1995, 152 (5 Pt 2): S77-121.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"50_CR5","first-page":"465","volume":"113","author":"DW Gump","year":"1976","unstructured":"Gump DW, Phillips CA, Forsyth BR, McIntosh K, Lamborn KR, Stouch WH: Role of infection in chronic bronchitis. Am Rev Respir Dis. 1976, 113 (4): 465-474.","journal-title":"Am Rev Respir Dis"},{"issue":"4","key":"50_CR6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/infdis\/137.4.377","volume":"137","author":"RO Buscho","year":"1978","unstructured":"Buscho RO, Saxtan D, Shultz PS, Finch E, Mufson MA: Infections with viruses and Mycoplasma pneumoniae during exacerbations of chronic bronchitis. J Infect Dis. 1978, 137 (4): 377-383.","journal-title":"J Infect Dis"},{"issue":"2","key":"50_CR7","first-page":"225","volume":"121","author":"CB Smith","year":"1980","unstructured":"Smith CB, Golden CA, Kanner RE, Renzetti ADJ: Association of viral and Mycoplasma pneumoniae infections with acute respiratory illness in patients with chronic obstructive pulmonary diseases. Am Rev Respir Dis. 1980, 121 (2): 225-232.","journal-title":"Am Rev Respir Dis"},{"issue":"1","key":"50_CR8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1183\/09031936.93.06010019","volume":"6","author":"F Blasi","year":"1993","unstructured":"Blasi F, Legnani D, Lombardo VM, Negretto GG, Magliano E, Pozzoli R, Chiodo F, Fasoli A, Allegra L: Chlamydia pneumoniae infection in acute exacerbations of COPD. Eur Respir J. 1993, 6 (1): 19-22.","journal-title":"Eur Respir J"},{"issue":"4","key":"50_CR9","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1378\/chest.114.4.969","volume":"114","author":"N Miyashita","year":"1998","unstructured":"Miyashita N, Niki Y, Nakajima M, Kawane H, Matsushima T: Chlamydia pneumoniae infection in patients with diffuse panbronchiolitis and COPD. Chest. 1998, 114 (4): 969-971.","journal-title":"Chest"},{"key":"50_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/jac\/43.suppl_1.97","volume":"43 Suppl A","author":"S Sethi","year":"1999","unstructured":"Sethi S: Infectious exacerbations of chronic bronchitis: diagnosis and management. J Antimicrob Chemother. 1999, 43 Suppl A: 97-105. 10.1093\/jac\/43.suppl_1.97","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"50_CR11","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1001\/jama.1995.03520360071042","volume":"273","author":"S Saint","year":"1995","unstructured":"Saint S, Bent S, Vittinghoff E, Grady D: Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. Jama. 1995, 273 (12): 957-960. 10.1001\/jama.273.12.957","journal-title":"Jama"},{"issue":"2","key":"50_CR12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1006\/pupt.2001.0289","volume":"14","author":"L Allegra","year":"2001","unstructured":"Allegra L, Blasi F, de Bernardi B, Cosentini R, Tarsia P: Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: a re-evaluation of previously published data of a placebo-controlled randomized study. Pulm Pharmacol Ther. 2001, 14 (2): 149-155. 10.1006\/pupt.2001.0289","journal-title":"Pulm Pharmacol Ther"},{"key":"50_CR13","doi-asserted-by":"publisher","first-page":"196","DOI":"10.7326\/0003-4819-106-2-196","volume":"106","author":"NR Anthonisen","year":"1987","unstructured":"Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA: Antibiotic Therapy in Exacerbations of Chronic Obstructive Pulmonary Disease. Annals of Internal Medicine. 1987, 106: 196-204.","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"50_CR14","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/S0149-2918(02)85139-6","volume":"24","author":"R Wilson","year":"2002","unstructured":"Wilson R, Schentag JJ, Ball P, Mandell L: A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther. 2002, 24 (4): 639-652. 10.1016\/S0149-2918(02)85139-6","journal-title":"Clin Ther"},{"issue":"7","key":"50_CR15","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1136\/thorax.58.7.589","volume":"58","author":"S Spencer","year":"2003","unstructured":"Spencer S, Jones PW, Group GLOBES: Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax. 2003, 58 (7): 589-593. 10.1136\/thorax.58.7.589","journal-title":"Thorax"},{"issue":"2","key":"50_CR16","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1128\/CMR.14.2.336-363.2001","volume":"14","author":"S Sethi","year":"2001","unstructured":"Sethi S, Murphy TF: Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev. 2001, 14 (2): 336-363. 10.1128\/CMR.14.2.336-363.2001","journal-title":"Clin Microbiol Rev"},{"issue":"1 Pt 2","key":"50_CR17","doi-asserted-by":"publisher","first-page":"12S","DOI":"10.1592\/phco.22.2.12S.33134","volume":"22","author":"CJ Destache","year":"2002","unstructured":"Destache CJ: Optimizing economic outcomes in acute exacerbations of chronic bronchitis. Pharmacotherapy. 2002, 22 (1 Pt 2): 12S-17S; discussion 30S-32S. 10.1592\/phco.22.2.12S.33134","journal-title":"Pharmacotherapy"},{"key":"50_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/jac\/dkf810","volume":"50 Suppl S1","author":"D Hoban","year":"2002","unstructured":"Hoban D, Felmingham D: The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections. J Antimicrob Chemother. 2002, 50 Suppl S1: 49-59.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"50_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/jac\/dkg321","volume":"52","author":"MR Jacobs","year":"2003","unstructured":"Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN: The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother. 2003, 52 (2): 229-246. 10.1093\/jac\/dkg321","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"50_CR20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1046\/j.1365-2958.2000.01841.x","volume":"36","author":"S Douthwaite","year":"2000","unstructured":"Douthwaite S, Hansen LH, Mauvais P: Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA. Mol Microbiol. 2000, 36 (1): 183-193. 10.1046\/j.1365-2958.2000.01841.x","journal-title":"Mol Microbiol"},{"issue":"6","key":"50_CR21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1054\/drup.2000.0175","volume":"3","author":"P Zhong","year":"2000","unstructured":"Zhong P, Shortridge VD: The role of efflux in macrolide resistance. Drug Resist Updat. 2000, 3 (6): 325-329. 10.1054\/drup.2000.0175","journal-title":"Drug Resist Updat"},{"key":"50_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jac\/dkf806","volume":"50 Suppl S1","author":"DJ Farrell","year":"2002","unstructured":"Farrell DJ, Morrissey I, Bakker S, Felmingham D: Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study. J Antimicrob Chemother. 2002, 50 Suppl S1: 39-47.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"50_CR23","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1128\/AAC.47.6.1777-1783.2003","volume":"47","author":"DJ Farrell","year":"2003","unstructured":"Farrell DJ, Douthwaite S, Morrissey I, Bakker S, Poehlsgaard J, Jakobsen L, Felmingham D: Macrolide Resistance by Ribosomal Mutation in Clinical Isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 Study. Antimicrob Agents Chemother. 2003, 47 (6): 1777-1783. 10.1128\/AAC.47.6.1777-1783.2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"90002","key":"50_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkf807","volume":"50","author":"D Felmingham","year":"2002","unstructured":"Felmingham D: The need for antimicrobial resistance surveillance. J Antimicrob Chemother. 2002, 50 (90002): 1-7.","journal-title":"J Antimicrob Chemother"},{"key":"50_CR25","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard - Fifth Edition","author":"NCCLS","year":"2000","unstructured":"NCCLS: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard - Fifth Edition. NCCLS document M7 - A5. 2000, Wayne, Pennsylvania 19087 - 1898, USA,"},{"key":"50_CR26","volume-title":"Performance standards antimicrobial susceptibility testing; Twelfth information supplement","author":"NCCLS","year":"2002","unstructured":"NCCLS: Performance standards antimicrobial susceptibility testing; Twelfth information supplement. NCCLS document M100 - 12. 2002, Wayne, Pennsylvania 19807 - 1898, USA , NCCLS,"},{"key":"50_CR27","volume-title":"Performance standards antimicrobial susceptibility testing; Twelfth information supplement","author":"NCCLS","year":"2004","unstructured":"NCCLS: Performance standards antimicrobial susceptibility testing; Twelfth information supplement.NCCLS document M100-S14. 2004, Wayne, Pennsylvania 19807 - 1898, USA , NCCLS,"},{"issue":"5 Suppl 2","key":"50_CR28","doi-asserted-by":"publisher","first-page":"380S","DOI":"10.1378\/chest.117.5_suppl_2.380S","volume":"117","author":"S Sethi","year":"2000","unstructured":"Sethi S: Infectious etiology of acute exacerbations of chronic bronchitis. Chest. 2000, 117 (5 Suppl 2): 380S-5S. 10.1378\/chest.117.5_suppl_2.380S","journal-title":"Chest"},{"issue":"11","key":"50_CR29","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1056\/NEJM197503132921105","volume":"292","author":"I Tager","year":"1975","unstructured":"Tager I, Speizer FE: Role of infection in chronic bronchitis. N Engl J Med. 1975, 292 (11): 563-571.","journal-title":"N Engl J Med"},{"issue":"4","key":"50_CR30","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1164\/ajrccm\/146.4.1067","volume":"146","author":"TF Murphy","year":"1992","unstructured":"Murphy TF, Sethi S: Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1992, 146 (4): 1067-1083.","journal-title":"Am Rev Respir Dis"},{"issue":"4","key":"50_CR31","first-page":"243","volume":"8","author":"CM Isada","year":"1993","unstructured":"Isada CM: Pro: antibiotics for chronic bronchitis with exacerbations. Semin Respir Infect. 1993, 8 (4): 243-253.","journal-title":"Semin Respir Infect"},{"issue":"1","key":"50_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11908-003-0059-x","volume":"5","author":"S Sethi","year":"2003","unstructured":"Sethi S: The Role of Antibiotics in Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Curr Infect Dis Rep. 2003, 5 (1): 9-15.","journal-title":"Curr Infect Dis Rep"},{"issue":"7","key":"50_CR33","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1056\/NEJMoa012561","volume":"347","author":"S Sethi","year":"2002","unstructured":"Sethi S, Evans N, Grant BJ, Murphy TF: New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002, 347 (7): 465-471. 10.1056\/NEJMoa012561","journal-title":"N Engl J Med"},{"key":"50_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/31.suppl_A.1","volume":"31 Suppl A","author":"RCJ Moellering","year":"1993","unstructured":"Moellering RCJ: Meeting the challenges of beta-lactamases. J Antimicrob Chemother. 1993, 31 Suppl A: 1-8.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"50_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3201\/eid0901.020277","volume":"9","author":"WM Scheld","year":"2003","unstructured":"Scheld WM: Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis. 2003, 9 (1): 1-9.","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"50_CR36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1089\/mdr.2004.10.255","volume":"10","author":"CE Nord","year":"2004","unstructured":"Nord CE, Farrell DJ, Leclercq R: Impact of ketolides on resistance selection and ecologic effects during treatment for respiratory tract infections. Microb Drug Resist. 2004, 10 (3): 255-263.","journal-title":"Microb Drug Resist"},{"issue":"3","key":"50_CR37","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/jac\/48.3.403","volume":"48","author":"N Miyashita","year":"2001","unstructured":"Miyashita N, Fukano H, Niki Y, Matsushima T: In vitro activity of telithromycin, a new ketolide, against Chlamydia pneumoniae. J Antimicrob Chemother. 2001, 48 (3): 403-405. 10.1093\/jac\/48.3.403","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"50_CR38","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1128\/AAC.43.1.90","volume":"43","author":"PH Edelstein","year":"1999","unstructured":"Edelstein PH, Edelstein MA: In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia. Antimicrob Agents Chemother. 1999, 43 (1): 90-95.","journal-title":"Antimicrob Agents Chemother"},{"key":"50_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/jac\/48.suppl_2.25","volume":"48 Suppl T1","author":"MR Hammerschlag","year":"2001","unstructured":"Hammerschlag MR, Roblin PM, Bebear CM: Activity of telithromycin, a new ketolide antibacterial, against atypical and intracellular respiratory tract pathogens. J Antimicrob Chemother. 2001, 48 Suppl T1: 25-31.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"50_CR40","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1093\/jac\/47.6.837","volume":"47","author":"OA Khair","year":"2001","unstructured":"Khair OA, Andrews JM, Honeybourne D, Jevons G, Vacheron F, Wise R: Lung concentrations of telithromycin after oral dosing. J Antimicrob Chemother. 2001, 47 (6): 837-840. 10.1093\/jac\/47.6.837","journal-title":"J Antimicrob Chemother"},{"key":"50_CR41","first-page":"11","volume":"29 Suppl 2","author":"DP Nicolau","year":"2001","unstructured":"Nicolau DP: Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles. Infection. 2001, 29 Suppl 2: 11-15.","journal-title":"Infection"},{"issue":"5","key":"50_CR42","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1093\/jac\/46.5.741","volume":"46","author":"C Edlund","year":"2000","unstructured":"Edlund C, Alvan G, Barkholt L, Vacheron F, Nord CE: Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora. J Antimicrob Chemother. 2000, 46 (5): 741-749. 10.1093\/jac\/46.5.741","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"50_CR43","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1053\/rmed.2002.1382","volume":"96","author":"M Aubier","year":"2002","unstructured":"Aubier M, Aldons PM, Leak A, McKeith DD, Leroy B, Rangaraju M, Bienfait-Beuzon C: Telithromycin is as effective as amoxicillin\/clavulanate in acute exacerbations of chronic bronchitis. Respir Med. 2002, 96 (11): 862-871. 10.1053\/rmed.2002.1382","journal-title":"Respir Med"},{"issue":"12","key":"50_CR44","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.2165\/00003495-200262120-00006","volume":"62","author":"GG Zhanel","year":"2002","unstructured":"Zhanel GG, Walters M, Noreddin A, Vercaigne LM, Wierzbowski A, Embil JM, Gin AS, Douthwaite S, Hoban DJ: The ketolides: a critical review. Drugs. 2002, 62 (12): 1771-1804.","journal-title":"Drugs"}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-0711-4-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T16:28:59Z","timestamp":1683044939000},"score":1,"resource":{"primary":{"URL":"https:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/1476-0711-4-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,8]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["50"],"URL":"https:\/\/doi.org\/10.1186\/1476-0711-4-5","relation":{},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3,8]]},"assertion":[{"value":"8 February 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"5"}}